Emergent BioSolutions Names Interim CFO Amid Leadership Transition
Emergent BioSolutions (NYSE: EBS) announced on October 16, 2026 that CFO Richard Lindahl will retire, with Frank Vargo appointed interim CFO. The move occurs during heightened FDA scrutiny and pipeline transition—making financial leadership continuity critical for SEC compliance and investor confidence.
51CFO view：CFO transitions at public companies trigger SEC disclosure obligations (Form 8-K Item 4.02) if the interim lacks full SOX 404 experience or recent 10-K/10-Q involvement. Pre-IPO firms should prioritize candidates with proven ‘interim CFO’ track records to avoid control deficiencies.
Emergent BioSolutions (NYSE: EBS) announced on October 16, 2026 that CFO Richard Lindahl will retire, with Frank Vargo appointed interim CFO. The move occurs during heightened FDA scrutiny and pipeline transition—making financial leadership continuity critical for SEC compliance and investor confidence.
Source：Google News · CFO 任命
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
How is a US-listed CFO paid?
Base, equity incentive and listing-milestone bonus: structure and ranges.
Read →
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →